159 related articles for article (PubMed ID: 29953319)
1. FcγRIIIa-dependent IFN-γ release in whole blood assay is predictive of therapeutic IgG1 antibodies safety.
Alakhras NS; Qiu J; Rocha GV; Witcher DR; Koester A; You J; Schaer DA; Holmgaard RB; Driscoll K; Willy JA; Malherbe LP
MAbs; 2018; 10(6):913-921. PubMed ID: 29953319
[TBL] [Abstract][Full Text] [Related]
2. Impact of Human FcγR Gene Polymorphisms on IgG-Triggered Cytokine Release: Critical Importance of Cell Assay Format.
Hussain K; Hargreaves CE; Rowley TF; Sopp JM; Latham KV; Bhatta P; Sherington J; Cutler RM; Humphreys DP; Glennie MJ; Strefford JC; Cragg MS
Front Immunol; 2019; 10():390. PubMed ID: 30899264
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells.
Wing MG; Moreau T; Greenwood J; Smith RM; Hale G; Isaacs J; Waldmann H; Lachmann PJ; Compston A
J Clin Invest; 1996 Dec; 98(12):2819-26. PubMed ID: 8981930
[TBL] [Abstract][Full Text] [Related]
4. Extracorporeal human whole blood in motion, as a tool to predict first-infusion reactions and mechanism-of-action of immunotherapeutics.
Fletcher EAK; Eltahir M; Lindqvist F; Rieth J; Törnqvist G; Leja-Jarblad J; Mangsbo SM
Int Immunopharmacol; 2018 Jan; 54():1-11. PubMed ID: 29100032
[TBL] [Abstract][Full Text] [Related]
5. Development of the first reference antibody panel for qualification and validation of cytokine release assay platforms - Report of an international collaborative study.
Vessillier S; Fort M; O'Donnell L; Hinton H; Nadwodny K; Piccotti J; Rigsby P; Staflin K; Stebbings R; Mekala D; Willingham A; Wolf B;
Cytokine X; 2020 Dec; 2(4):100042. PubMed ID: 33458650
[TBL] [Abstract][Full Text] [Related]
6. Recombinant H22(scFv) blocks CD64 and prevents the capture of anti-TNF monoclonal antibody. A potential strategy to enhance anti-TNF therapy.
Hristodorov D; Mladenov R; Brehm H; Fischer R; Barth S; Thepen T
MAbs; 2014; 6(5):1283-9. PubMed ID: 25517313
[TBL] [Abstract][Full Text] [Related]
7. Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 Is independent of FcgammaRIIIa functional polymorphism.
Niwa R; Hatanaka S; Shoji-Hosaka E; Sakurada M; Kobayashi Y; Uehara A; Yokoi H; Nakamura K; Shitara K
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6248-55. PubMed ID: 15448014
[TBL] [Abstract][Full Text] [Related]
8. Horse cytokine/IgG fusion proteins--mammalian expression of biologically active cytokines and a system to verify antibody specificity to equine cytokines.
Wagner B; Robeson J; McCracken M; Wattrang E; Antczak DF
Vet Immunol Immunopathol; 2005 May; 105(1-2):1-14. PubMed ID: 15797470
[TBL] [Abstract][Full Text] [Related]
9. Cytokine release assays for the prediction of therapeutic mAb safety in first-in man trials--Whole blood cytokine release assays are poorly predictive for TGN1412 cytokine storm.
Vessillier S; Eastwood D; Fox B; Sathish J; Sethu S; Dougall T; Thorpe SJ; Thorpe R; Stebbings R
J Immunol Methods; 2015 Sep; 424():43-52. PubMed ID: 25960173
[TBL] [Abstract][Full Text] [Related]
10. The "less-is-more" in therapeutic antibodies: Afucosylated anti-cancer antibodies with enhanced antibody-dependent cellular cytotoxicity.
Pereira NA; Chan KF; Lin PC; Song Z
MAbs; 2018 Jul; 10(5):693-711. PubMed ID: 29733746
[TBL] [Abstract][Full Text] [Related]
11. An Fc engineering approach that modulates antibody-dependent cytokine release without altering cell-killing functions.
Kinder M; Greenplate AR; Strohl WR; Jordan RE; Brezski RJ
MAbs; 2015; 7(3):494-504. PubMed ID: 25933349
[TBL] [Abstract][Full Text] [Related]
12. A therapeutic human IgG4 monoclonal antibody that depletes target cells in humans.
Isaacs JD; Wing MG; Greenwood JD; Hazleman BL; Hale G; Waldmann H
Clin Exp Immunol; 1996 Dec; 106(3):427-33. PubMed ID: 8973608
[TBL] [Abstract][Full Text] [Related]
13. Expression of human FcgammaRIIIa as a GPI-linked molecule on CHO cells to enable measurement of human IgG binding.
Armour KL; Smith CS; Clark MR
J Immunol Methods; 2010 Mar; 354(1-2):20-33. PubMed ID: 20138184
[TBL] [Abstract][Full Text] [Related]
14. Selective correlation of interferon-gamma, tumour necrosis factor-alpha and granulocyte-macrophage colony-stimulating factor with immunoglobulin G1 and immunoglobulin G3 subclass antibody in leprosy.
Hussain R; Kifayet A; Dojki M; Dockrell HM
Immunology; 1999 Oct; 98(2):238-43. PubMed ID: 10540222
[TBL] [Abstract][Full Text] [Related]
15. Induction of mouse IgG2a- and IgG3-dependent cellular cytotoxicity in human monocytic cells (U937) by immune interferon.
Akiyama Y; Lubeck MD; Steplewski Z; Koprowski H
Cancer Res; 1984 Nov; 44(11):5127-31. PubMed ID: 6435864
[TBL] [Abstract][Full Text] [Related]
16. A whole blood in vitro cytokine release assay with aqueous monoclonal antibody presentation for the prediction of therapeutic protein induced cytokine release syndrome in humans.
Wolf B; Morgan H; Krieg J; Gani Z; Milicov A; Warncke M; Brennan F; Jones S; Sims J; Kiessling A
Cytokine; 2012 Dec; 60(3):828-37. PubMed ID: 22986013
[TBL] [Abstract][Full Text] [Related]
17. Antitumor immune effector mechanisms recruited by phage display-derived fully human IgG1 and IgA1 monoclonal antibodies.
Huls G; Heijnen IA; Cuomo E; van der Linden J; Boel E; van de Winkel JG; Logtenberg T
Cancer Res; 1999 Nov; 59(22):5778-84. PubMed ID: 10582699
[TBL] [Abstract][Full Text] [Related]
18. Development of a human whole blood assay for prediction of cytokine release similar to anti-CD28 superagonists using multiplex cytokine and hierarchical cluster analysis.
Walker MR; Makropoulos DA; Achuthanandam R; Van Arsdell S; Bugelski PJ
Int Immunopharmacol; 2011 Nov; 11(11):1697-705. PubMed ID: 21689786
[TBL] [Abstract][Full Text] [Related]
19. A phase I study of interleukin 12 with trastuzumab in patients with human epidermal growth factor receptor-2-overexpressing malignancies: analysis of sustained interferon gamma production in a subset of patients.
Parihar R; Nadella P; Lewis A; Jensen R; De Hoff C; Dierksheide JE; VanBuskirk AM; Magro CM; Young DC; Shapiro CL; Carson WE
Clin Cancer Res; 2004 Aug; 10(15):5027-37. PubMed ID: 15297404
[TBL] [Abstract][Full Text] [Related]
20. Immunological analysis of the murine anti-CD3-induced cytokine release syndrome model and therapeutic efficacy of anti-cytokine antibodies.
Nouveau L; Buatois V; Cons L; Chatel L; Pontini G; Pleche N; Ferlin WG
Eur J Immunol; 2021 Aug; 51(8):2074-2085. PubMed ID: 33945643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
